<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;C03B&quot;,&quot;href&quot;:&quot;atc/C03B.md&quot;},{&quot;label&quot;:&quot;chlortalidone&quot;}]"></div>

# chlortalidone

- **generic name:** chlortalidone
- **ATC codes:** `C03BA04`, `C03BB04`, `C03EA06`
- **DrugBank:** [DB00310](https://go.drugbank.com/drugs/DB00310) · **PubChem:** not captured
- **groups:** approved, investigational

## About

Chlortalidone is a diuretic and antihypertensive drug used to treat arterial hypertension, congestive heart failure, and fluid retention conditions such as anasarca and nephrotic syndrome, and also nephrogenic diabetes insipidus. It is an approved medicine, available alone or in combination products with potassium-sparing agents or potassium, and is used widely in cardiovascular care.

<small>Summary written by `glm-5.3-flash` from [Wikidata Q425289](https://www.wikidata.org/wiki/Q425289) and the WHO ATC classification; not checked by a person.</small>

## Molecules and molar masses

> The molar mass each model uses to convert mass to molar concentration and to form a metabolite molecule for molecule. Looked up, never estimated: DrugBank for the drug, the paper's own value or the PubChem entry matched to the paper's name for a metabolite.

| molecule | role | molar mass (g/mol) | formula | source | PubChem | records |
|---|---|---|---|---|---|---|
| chlortalidone (chlorthalidone) | parent | 338.762 | C14H11ClN2O4S | PubChem | [2732](https://pubchem.ncbi.nlm.nih.gov/compound/2732) | Fleuren_1979 |

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-06 17:11 | 7:06 | 0/1/0 | 0/0/0 | 0/0/8 | 141,956/17,674 | ollama / qwen3.8:27b-mtp-q8_0 | 9 | 0/8 | 8/1 | 0 |

## popPK records

| status | detail | model | model structure | params | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--stale">stale</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.2). The first reading is what the record holds.">cross-check: disputed</span><br><sub>STALE — current validate: rejected</sub><br><sub>blocking: no distribution volume and no clearance/elimination — not a compartmental popPK…</sub><br><sub>route_to: `human_review`</sub> | [Fleuren_1979_reference](drugs/drug_chlortalidone/Chlortalidone_Fleuren1979_reference.md) | — | 1-compartment (no model) | 2 | Fleuren HL et al., Absolute bioavailability of chlorthalid…, European journal of clinica… (1979) | [10.1007/BF00563556](https://doi.org/10.1007/BF00563556) |

## Pharmacogenomics (PGx)

| status | gene | affects | mechanism | detail | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--neutral" title="the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.">qualitative</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss:120b (?, agreement 0.25). The first reading is what the record holds.">cross-check: partial</span> | **CACNA1C** | `Q100` — no parameter target — an association/risk finding, not a parameter shift | target | [Armstrong_2022](drugs/drug_chlortalidone/pgx_Armstrong_2022_CACNA1C_Q100.md) | Armstrong ND et al., Genetic Contributors of Efficacy and Ad…, Genes (2022) | [10.3390/genes13071260](https://doi.org/10.3390/genes13071260) |
| <span class="pk-badge pk-badge--neutral" title="the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.">qualitative</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss:120b (?, agreement 0.25). The first reading is what the record holds.">cross-check: partial</span> | **GIMAP1-GIMAP5** | `Q100` — no parameter target — an association/risk finding, not a parameter shift | unknown | [Armstrong_2022](drugs/drug_chlortalidone/pgx_Armstrong_2022_GIMAP1_GIMAP5_Q100.md) | Armstrong ND et al., Genetic Contributors of Efficacy and Ad…, Genes (2022) | [10.3390/genes13071260](https://doi.org/10.3390/genes13071260) |
| <span class="pk-badge pk-badge--neutral" title="the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.">qualitative</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss:120b (?, agreement 0.25). The first reading is what the record holds.">cross-check: partial</span> | **LINC02211-CDH9** | `Q100` — no parameter target — an association/risk finding, not a parameter shift | unknown | [Armstrong_2022](drugs/drug_chlortalidone/pgx_Armstrong_2022_LINC02211_CDH9_Q100.md) | Armstrong ND et al., Genetic Contributors of Efficacy and Ad…, Genes (2022) | [10.3390/genes13071260](https://doi.org/10.3390/genes13071260) |
| <span class="pk-badge pk-badge--neutral" title="the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.">qualitative</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss:120b (?, agreement 0.25). The first reading is what the record holds.">cross-check: partial</span> | **HMGCS2** | `Q100` — no parameter target — an association/risk finding, not a parameter shift | target | [Singh_2018](drugs/drug_chlortalidone/pgx_Singh_2018_HMGCS2_Q100.md) | Singh S et al., Genome Wide Association Study Identifie…, Journal of the American Hea… (2018) | [10.1161/JAHA.117.007339](https://doi.org/10.1161/JAHA.117.007339) |
| <span class="pk-badge pk-badge--neutral" title="the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.">qualitative</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss:120b (?, agreement 0.25). The first reading is what the record holds.">cross-check: partial</span> | **DUSP1** | `Q100` — no parameter target — an association/risk finding, not a parameter shift | target | [Sá_2018](drugs/drug_chlortalidone/pgx_S_2018_DUSP1_Q100.md) | Sá ACC et al., Blood pressure signature genes and bloo…, BMC medical genomics (2018) | [10.1186/s12920-018-0370-x](https://doi.org/10.1186/s12920-018-0370-x) |
| <span class="pk-badge pk-badge--neutral" title="the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.">qualitative</span> <span class="pk-badge pk-badge--green" title="re-read by gpt-oss:120b (confirmed, agreement 1.0). The first reading is what the record holds.">cross-checked ✓</span> | **FOS** | `Q100` — no parameter target — an association/risk finding, not a parameter shift | target | [Sá_2018](drugs/drug_chlortalidone/pgx_S_2018_FOS_Q100.md) | Sá ACC et al., Blood pressure signature genes and bloo…, BMC medical genomics (2018) | [10.1186/s12920-018-0370-x](https://doi.org/10.1186/s12920-018-0370-x) |
| <span class="pk-badge pk-badge--neutral" title="the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.">qualitative</span> <span class="pk-badge pk-badge--green" title="re-read by gpt-oss:120b (confirmed, agreement 1.0). The first reading is what the record holds.">cross-checked ✓</span> | **PPP1R15A** | `Q100` — no parameter target — an association/risk finding, not a parameter shift | target | [Sá_2018](drugs/drug_chlortalidone/pgx_S_2018_PPP1R15A_Q100.md) | Sá ACC et al., Blood pressure signature genes and bloo…, BMC medical genomics (2018) | [10.1186/s12920-018-0370-x](https://doi.org/10.1186/s12920-018-0370-x) |
| <span class="pk-badge pk-badge--neutral" title="the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.">qualitative</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss:120b (?, agreement 0.25). The first reading is what the record holds.">cross-check: partial</span> | **SLC12A3** | `Q100` — no parameter target — an association/risk finding, not a parameter shift | transport | [Xu_2026](drugs/drug_chlortalidone/pgx_Xu_2026_SLC12A3_Q100.md) | Xu C et al., Unmasking of a Heterozygous SLC12A3 Var…, Kidney medicine (2026) | [10.1016/j.xkme.2026.101255](https://doi.org/10.1016/j.xkme.2026.101255) |

<details class="pk-legend"><summary>What the PGx badges mean — evidence, and whether a model runs</summary><table><tbody><tr><td><span class="pk-badge pk-badge--green">quantitative</span></td><td>the paper gives the effect of each phenotype (or genotype) on a named model parameter — a θ per category.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">qualitative</span></td><td>the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">guideline estimate</span></td><td>the effect comes from a CPIC / DPWG dosing guideline, not from this paper's numbers.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">safety allele</span></td><td>a risk allele for an adverse reaction (an HLA type, G6PD deficiency …): it changes no PK/PD parameter.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>the extraction is incomplete or inconsistent.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted.</td></tr><tr><td><span class="pk-badge pk-badge--green">▶ simulatable</span></td><td>the paper's popPK model runs per phenotype in the browser (Simulation tab); its PGx Modelica model is under Models.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">model only</span></td><td>a PGx Modelica model exists but has no in-browser simulator.</td></tr></tbody></table></details>

<details class="legend">
<summary>What the PGx columns mean</summary>
<table><thead><tr><th>column</th><th>what it holds</th></tr></thead><tbody><tr><td><code>gene</code></td><td>the gene whose variants the record is about. One record per gene, so a paper reporting several genes appears on several rows.</td></tr><tr><td><code>affects</code></td><td>the PK or PD parameter the genotype SHIFTS, as an ontology Q-code plus its name — Q22 = clearance, Q27 = CL/F (apparent clearance), Q32 = Cmax, Q88 = AUC, Q40 = Fab, Q321 = EC50, Q322 = IC50, Q305 = kfm. The record's per-phenotype theta is a multiplier ON that parameter: a poor-metaboliser theta shifts this value, it does not supply one. Two values are NOT parameters — Q100 (NIL) is an association or risk finding with no parameter target, and `safety` is an adverse-reaction risk such as an HLA allele. A PA… id instead of a Q-code marks a record derived from a ClinPGx/PharmGKB guideline lookup rather than read out of the paper.</td></tr><tr><td><code>mechanism</code></td><td>how the gene acts: metabolism, transport, target, formation, safety_allele, or unknown.</td></tr><tr><td><code>detail</code></td><td>the paper stem, linking to the full record page.</td></tr><tr><th colspan="2" style="text-align:left;padding-top:10px">placeholders</th></tr><tr><td><code>not captured</code></td><td>the field is absent from the KB artifact — nothing was recorded. This is NOT the same as zero or empty: the value is unknown, not measured to be nothing.</td></tr><tr><td><code>—</code></td><td>deliberately not shown: the column does not apply to this row.</td></tr><tr><td><code>not verified</code></td><td>the record is not in an accepted state (see the badge and the note above the table); the numbers are shown as extracted, not endorsed.</td></tr></tbody></table>
</details>

## ADME sites

Where this drug is handled, from DrugBank's curated enzymes / transporters / carriers and the KB's PGx genes, mapped to tissue through the ADME gene table. Compare it with other drugs on the [Sites & interactions](sites?drugs=chlortalidone) page (add drugs there; the set becomes a link).

| process | tissue | actors (role) | evidence |
|---|---|---|---|
| distribution | blood | `ALB` unknown | DrugBank actor |
| metabolism | liver | <sub>named in DrugBank's ADME text</sub> | prose |
| excretion | kidney | <sub>named in DrugBank's ADME text</sub> | prose |

<sub>Actors without a tissue in the table: CA1 (inhibitor), CACNA1C (target), DUSP1 (target), FOS (target), GIMAP1-GIMAP5 (unknown), HMGCS2 (target), LINC02211-CDH9 (unknown), PPP1R15A (target), SLC12A1 (inhibitor), SLC12A3 (transport).</sub>

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr><tr><td><span class="pk-badge pk-badge--species">rat</span></td><td>the data come from an animal (or in-vitro) study, not from people. The record, its model and its simulation are kept — they describe that species.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 65 matched, 50 returned
- **screened:** 6  ·  **relevant:** 1
- **records:** 1  ·  extracted 0  ·  needs_review 0  ·  rejected 1  ·  stale 1
- **scholar-agent fallback query used:** True

## Full text wanted

_6 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Fleuren_1979.pdf` | Fleuren HL et al., Absolute bioavailability of chlorthalid…, European journal of clinica… (1979) | popPK | 10 | [10.1007/BF00563556](https://doi.org/10.1007/BF00563556) | [421727](https://pubmed.ncbi.nlm.nih.gov/421727) | The study reports quantitative pharmacokinetic parameters including half-lives, bioavailability, and compartmental model descriptions for chlorthalidone in humans. |
| `MacGregor_1985.pdf` | MacGregor TR et al., Chlorthalidone pharmacodynamics in beag…, Journal of pharmaceutical s… (1985) | popPK | 9 | [10.1002/jps.2600740810](https://doi.org/10.1002/jps.2600740810) | [4032269](https://pubmed.ncbi.nlm.nih.gov/4032269) | The study reports a compartmental PK model and bioequivalence for chlortalidone in dogs, but specific numeric parameter values (CL, V, ka) are not present in the provided abstract text. |
| `Pentikis_1996.pdf` | Pentikis HS et al., Bioequivalence: individual and populati…, Pharmaceutical research (1996) | popPK | 9 | [10.1023/a:1016083429903](https://doi.org/10.1023/a:1016083429903) | [8842055](https://pubmed.ncbi.nlm.nih.gov/8842055) | The study analyzes chlorthalidone bioequivalence data using compartmental and population PK models, but the specific numeric parameter values are not present in the provided evidence. |
| `Kumar_2017.pdf` | Kumar Puttrevu S et al., Pharmacokinetic-pharmacodynamic modelin…, Naunyn-Schmiedeberg's archi… (2017) | pd | 5 | [10.1007/s00210-017-1339-6](https://doi.org/10.1007/s00210-017-1339-6) | [28190245](https://www.ncbi.nlm.nih.gov/pubmed/28190245) | metadata signals extractable PD data (pharmacodynamicmodel) |
| `Tsai_2016.pdf` | Tsai MC et al., Population Pharmacokinetics and Exposur…, Journal of clinical pharmac… (2016) | pd | 5 | [10.1002/jcph.684](https://doi.org/10.1002/jcph.684) | [26632101](https://www.ncbi.nlm.nih.gov/pubmed/26632101) | metadata signals extractable PD data (Exposure-Response) |
| `Yang_2022.pdf` | Yang S et al., Genetic variation of pharmacogenomic VI…, Molecular genetics and geno… (2022) | pgx | 5 | [10.1007/s00438-022-01855-9](https://doi.org/10.1007/s00438-022-01855-9) | [35146537](https://www.ncbi.nlm.nih.gov/pubmed/35146537) | metadata signals extractable PGX data (CYP4F2) |

<sub>queue written 2026-10-06T17:04:18.500683+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| PD | Angeloni_2016 | not_relevant | 1 | 0 | The paper is a qualitative review of azilsartan and its combinations, providing no numeric pharmacodynamic parameters or exposure-response data for chlortalidone. |
| PGx | Arnett_2005 | not_relevant | 0 | 0 | The study reports null results for the association between ACE genotype and cardiovascular outcomes, not a pharmacokinetic or pharmacodynamic parameter of chlortalidone. |
| PD | Blowey_2016 | not_relevant | 1 | 0 | The text is a general review of diuretics in hypertension and mentions chlorthalidone qualitatively without providing any numeric pharmacodynamic parameters, exposure-response data, or dose-effect curves. |
| PD | Bottino_2026 | not_relevant | 2 | 1 | The paper reports a comparative clinical trial with fixed doses (25 mg vs 50 mg) and qualitative dose-response observations for amiloride, but it does not provide a concentration-effect model, PK/PD fit, or numeric PD parameters (Emax, EC50) for chlortalidone. |
| PD | Carter_2004 | not_relevant | 2 | 1 | The paper is a review that qualitatively states chlorthalidone is 1.5-2.0 times more potent than hydrochlorothiazide but does not provide specific numeric PD parameters (e.g., EC50, Emax) or concentration-effect curves for chlorthalidone itself. |
| PD | Chrysant_2021 | not_relevant | 1 | 0 | The paper is a narrative review comparing the clinical efficacy of chlorthalidone and hydrochlorothiazide, and it does not report any specific pharmacokinetic or pharmacodynamic modeling or numeric PD parameters. |
| PD | Engelhardt_1996 | not_relevant | 0 | 0 | The paper focuses on meloxicam's pharmacology and only qualitatively states that meloxicam did not influence chlorthalidone's diuretic effect, without providing any numeric PD parameters or exposure-response data for chlorthalidone. |
| PGx | Irvin_2010 | not_relevant | 2 | 5 | The study reports pharmacogenomic associations with a clinical outcome (fasting glucose) rather than a direct pharmacokinetic or pharmacodynamic parameter of chlorthalidone. |
| PD | Kendall_1981 | not_relevant | 1 | 0 | The text is an abstract that only qualitatively states that chlorthalidone does not influence metoprolol's beta-blocking action and that plasma levels are similar to monotherapy, without providing any numeric PD parameters, concentration-effect curves, or dose-response data for chlorthalidone. |
| popPK | Kumar_2017 | irrelevant | 0 | 0 | no_text gate: only 159 chars of text extracted (&lt; 400) |
| popPK | MacGregor_1985 | relevant | 9 | 2 | The study reports a compartmental PK model and bioequivalence for chlortalidone in dogs, but specific numeric parameter values (CL, V, ka) are not present in the provided abstract text. |
| popPK | Maggi_1985 | irrelevant | 0 | 0 | The study investigates the pharmacokinetics of fenquizone, not chlortalidone, which is only mentioned as a comparator. |
| popPK | Marzo_2000 | irrelevant | 2 | 0 | The study is a bioequivalence trial reporting only relative bioavailability metrics (Cmax, AUC, tmax) for a fixed-dose combination, without providing absolute quantitative disposition parameters (CL, V, ka) for chlortalidone. |
| PD | Marzo_2000 | not_relevant | 1 | 0 | The paper is a bioequivalence study that only qualitatively mentions overlapping pharmacodynamic results (blood pressure) without providing numeric PD parameters or concentration-effect data. |
| PD | McTavish_1990 | not_relevant | 0 | 0 | The paper is a review of cadralazine and only mentions chlorthalidone as a comparator in a qualitative efficacy statement, providing no PD model, exposure-response data, or numeric PD parameters for chlorthalidone. |
| PGx | Mehanna_2017 | not_relevant | 0 | 0 | The paper analyzes blood pressure response based on age and race, not on specific gene variants or genotypes. |
| PGx | Mehanna_2019 | not_relevant | 0 | 0 | The paper investigates plasma renin activity (PRA) as a predictive biomarker for blood pressure response, not a genetic variant or genotype. |
| PD | OReilly_1971 | not_relevant | 0 | 0 | The provided text is only the title of a study and does not contain the full text, data, or numeric PD parameters required to assess the pharmacodynamic relationship. |
| popPK | Pentikis_1996 | relevant | 9 | 0 | The study analyzes chlorthalidone bioequivalence data using compartmental and population PK models, but the specific numeric parameter values are not present in the provided evidence. |
| PD | Reilly_2010 | not_relevant | 1 | 0 | The text is a narrative review providing qualitative dose recommendations for hypertension and nephrolithiasis but does not report any numeric pharmacodynamic parameters (e.g., Emax, EC50) or quantitative exposure-response/dose-response curves for chlortalidone. |
| PGx | Sørensen_2014 | not_relevant | 0 | 0 | The study investigates genetic associations with drug treatment groups (prescription patterns) rather than the effect of genotypes on pharmacokinetic or pharmacodynamic parameters. |
| PGx | Tanner_2011 | not_relevant | 0 | 0 | The paper reports pharmacogenomic associations with clinical cardiovascular outcomes (e.g., CHD, stroke), not pharmacokinetic or pharmacodynamic parameters of chlorthalidone. |
| popPK | Tsai_2016 | irrelevant | 0 | 0 | no_text gate: only 158 chars of text extracted (&lt; 400) |
| popPK | Turgeon_1994 | irrelevant | 0 | 0 | The study is an in-vitro electrophysiology investigation of ion channel block, not a pharmacokinetic study, and chlorthalidone was a comparator with no effect. |
| PD | Turgeon_1994 | not_relevant | 0 | 0 | The study reports that chlortalidone had no effect on IKs current, providing no numeric PD parameters or dose-response relationship for the drug. |
| PD | Turgeon_1995 | not_relevant | 3 | 2 | The paper reports a dose-response study but concludes that chlorthalidone had no protective effect, providing no numeric PD parameters (e.g., EC50, Emax) or derivable concentration-effect curve for the drug. |
| PGx | Yang_2022 | not_relevant | 0 | 0 | The paper reports population allele frequencies for VIP variants and mentions potential associations with chlorthalidone via PharmGKB, but it does not report any measured pharmacokinetic or pharmacodynamic parameters or effect sizes for chlorthalidone. |
| PD | Yoon_2026 | not_relevant | 2 | 1 | The paper is a pharmacovigilance and epidemiological cohort study assessing the risk of glaucoma (an adverse event) associated with drug use, not a pharmacodynamic study modeling the drug's therapeutic effect (e.g., blood pressure reduction) against exposure or dose. |
| PD | Zaiken_2011 | not_relevant | 0 | 0 | The paper is a review of azilsartan medoxomil and does not report any pharmacodynamic or exposure-response analysis for chlortalidone. |
| PD | de_1991 | not_relevant | 0 | 0 | The study reports PK parameter changes (clearance, volume of distribution) of a heparinoid induced by chlorthalidone, but does not report a pharmacodynamic (exposure-response or dose-response) relationship for chlorthalidone itself. |

---
<sub>Generated by `docs.py` (scholarv2) · newest extraction 2026-10-06 17:04 UTC</sub>
